Online inquiry

IVTScrip™ mRNA-Anti-EGFR, Fab C225(Cap 1, 2-Thio-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ7036MR)

This product GTTS-WQ7036MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 2-Thio-UTP. It ecodes the monoclonal antibody that targets EGFR gene. The antibody can be applied in Colorectal Cancer (CRC) Cancers (CRC) research.
Specifications
Product type mRNA
Modified bases 2-Thio-UTP
5' Cap Cap 1
Species Chimeric
RefSeq NM_001346897.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 1956
UniProt ID Q504U8
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-EGFR, Fab C225(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) (GTTS-WQ7036MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ1573MR IVTScrip™ mRNA-Anti-MSTN, ACE-083(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA ACE-083
GTTS-WQ2411MR IVTScrip™ mRNA-Anti-PCSK9, AMG 145(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA AMG 145
GTTS-WQ10425MR IVTScrip™ mRNA-Anti-IL17A, LY2439821(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA LY2439821
GTTS-WQ13885MR IVTScrip™ mRNA-Anti-PDGFRB, REGN-2176(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA REGN-2176
GTTS-WQ12911MR IVTScrip™ mRNA-Anti-FZD10, OTSA101-DTPA(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA OTSA101-DTPA
GTTS-WQ9682MR IVTScrip™ mRNA-Anti-CD19&CD3E, JNJ-64052781(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA JNJ-64052781
GTTS-WQ4555MR IVTScrip™ mRNA-Anti-CXCR4, BMS-936564(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA BMS-936564
GTTS-WQ11681MR IVTScrip™ mRNA-Anti-influenza B virus hemagglutinin, MHAB5553A(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA MHAB5553A
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW